This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.
AbbVie and J&J Present Positive Imbruvica Leukemia Data
by Zacks Equity Research
AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).
Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.
Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised
by Zacks Equity Research
Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.
Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.
Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.
Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.
Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance
by Zacks Equity Research
Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.
Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed
by Zacks Equity Research
Horizon Pharma plc (HZNP) reported first-quarter 2017 earnings of 21 cents per share, down from 25 cents in the year-ago quarter. Reported earnings also missed the Zacks Consensus Estimate of 25 cents.
Mallinckrodt Earnings, Revenues Beat Estimates in Q1
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported first-quarter 2017 results wherein both sales and earnings beat expectations.
ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 20 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of 36 cents and the year-ago loss of 37 cents.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Agenus Inc. (AGEN) reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents.
Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) reported first-quarter 2017 loss of 71 cents per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 66 cents.
Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents.
Zoetis (ZTS) Beats Earnings, Revenue Estimates in Q1
by Zacks Equity Research
Zoetis Inc. (ZTS) first-quarter 2017 earnings of 53 cents per share increased 10% year over year and surpassed the Zacks Consensus Estimate of 48 cents.
Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y
by Zacks Equity Research
Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.
AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates
by Zacks Equity Research
AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.
Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.
Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24 cents.
AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
Bayer (BAYRY) Beats Q1 Earnings, Revenue Estimates
by Zacks Equity Research
Bayer AG's (BAYRY) first-quarter 2017 core earnings per share from continuing operations was $2.80 which beat the Zacks Consensus Estimate of $2.40.
Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) first-quarter 2017 earnings (including stock-based compensation expense) of $1.20 per share compared with the year ago earnings of 76 cents. The reported figure surpassed the Zacks Consensus Estimate of $1.05.
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
by Zacks Equity Research
CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for the treatment of soft tissue sarcomas (STS).
Bet on Rising P/E with These 5 Top-Ranked Stocks
by Zacks Equity Research
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.